What question did this study set out to answer?

To investigate the association of SGLT2 inhibitors with stroke risk in type 2 diabetes patients with diabetic retinopathy.

April 15, 2026Open Access

Association of SGLT2 Inhibitor With Stroke in Type 2 Diabetes With Diabetic Retinopathy: A Multicenter Electronic Health Record Data Study

Key Points

To investigate the association of SGLT2 inhibitors with stroke risk in type 2 diabetes patients with diabetic retinopathy.
Multicenter study utilizing electronic health records.
Analysis focused on patients with type 2 diabetes and diabetic retinopathy.
Comparison of stroke incidence between those using SGLT2 inhibitors and those not.
SGLT2 inhibitors associated with a lower risk of stroke, particularly hemorrhagic stroke.
Findings indicate a potential cerebrovascular benefit for this medication class.

Abstract

SGLT2i was associated with lower stroke risk, particularly HS, in patients with T2D and DR. These findings suggest a potential cerebrovascular benefit, although prospective studies are needed to confirm this association.

Association of SGLT2 Inhibitor With Stroke in Type 2 Diabetes With Diabetic Retinopathy: A Multicenter Electronic Health Record Data Study

Key Points

Abstract

Cite This Study